James Basta has sold NTLA and made no open-market buys since Jan 2023

James Basta, J.D. is Executive Vice President, General Counsel, and Corporate Secretary at Intellia Therapeutics, Inc. (NTLA), a biotechnology company pioneering CRISPR-based genome editing therapies for severe diseases.( He joined Intellia in June 2021, after serving as Chief Legal Officer at Kura Oncology and as Senior Vice President, Chief Corporate Counsel at Biogen, where he oversaw securities filings, board matters, business development, finance, tax, corporate affairs, employment, and IT.(

With over 25 years of combined in-house and law firm experience, Basta previously was a Partner in the Corporate and Securities Practice Group at Baker & McKenzie.( He serves on the Executive Advisory Board of the Chemistry Life Processes Institute at Northwestern University and holds a J.D. and B.A. in economics from Northwestern University Pritzker School of Law and Northwestern University, respectively.( As a corporate insider, he recently traded NTLA shares, holding 111,925 shares valued at $1.05M as of his last reported sale on March 4, 2025.(

Written by Perplexity from public sources.